Protect brain health earlier. Evaluate changes sooner. Treat the drivers of decline—including inflammation—with a plan that matches the stage of disease.
Dementia is not one diagnosis and it is not inevitable for every person who ages. Alzheimer’s disease, vascular cognitive impairment, Lewy body disease, mixed pathology, and medication- or sleep-related decline can look similar at first. Chronic inflammation—in blood vessels, body fat, gums, airways, and the brain itself—can worsen that injury over time. Some risks can be reduced years before symptoms. Once memory or thinking changes appear, the goal shifts to accurate evaluation, slowing decline when possible, lowering inflammatory burden, treating symptoms, and supporting the person and their family.
Helix Advanced Medicine approaches brain health as medical care: risk assessment, structured evaluation, and a treatment plan based on stage and cause—not a single supplement or a guarantee of prevention.
There is no widely available cure for most dementias. Up to about 45% of dementia risk is linked to modifiable factors across the life course. Addressing those factors can delay or reduce risk for some people; it does not mean every case can be prevented.
Prevention: lowering risk before or early in decline
Prevention here means risk reduction and brain-health optimization, especially in midlife and later life. A Helix plan typically reviews and treats, when present:
- Vascular and metabolic risk — blood pressure, diabetes, cholesterol, obesity, smoking, and inactivity. These also drive vascular and systemic inflammation.
- Hearing and vision — untreated hearing loss is a major midlife risk; hearing aids and vision care are part of risk-reduction care.
- Sleep — screening for sleep apnea, insomnia, and fragmented sleep. Untreated apnea is a source of intermittent hypoxia and inflammatory stress.
- Medications — reducing or replacing drugs that cloud cognition when safer alternatives exist.
- Mood, alcohol, and social connection — depression, heavy alcohol use, and isolation are associated with higher dementia risk and are treatable.
- Physical activity, diet, and cognitive/social engagement — regular movement, a heart-healthy eating pattern, and ongoing mental and social activity.
- Inflammatory drivers — excess visceral fat, periodontal disease, poorly controlled diabetes, smoking, and chronic low-grade infection or airway disease.
Prevention visits are useful if you have a family history, midlife vascular disease, subjective memory concerns, or you simply want a structured brain-health plan.
Evaluation: finding the cause of change
If you or a family member notice memory lapses, word-finding trouble, getting lost, personality change, or declining independence, the first step is a proper workup—not assuming “it’s just aging.”
Evaluation may include detailed history from the patient and a family member; cognitive testing appropriate to the concern; review of medications, alcohol, sleep, mood, dental/oral health, and function; labs for reversible contributors and inflammatory/metabolic context (thyroid, B12, glucose/A1c, lipids, and other markers as indicated); and decision-making about imaging and, when appropriate, referral for specialist testing.
Inflammation is assessed as a contributor, not as a standalone diagnosis. Elevated inflammatory markers alone do not diagnose dementia and do not automatically justify a drug or infusion. For suspected Alzheimer’s disease in the appropriate clinical setting, care may include coordination of biomarker testing to confirm amyloid-related disease before considering disease-modifying therapy. Not every patient needs or qualifies for that pathway.
Treatment: matching therapy to the diagnosis and stage
Treatment depends on the cause and how far symptoms have progressed.
Reduction of inflammation (foundational treatment, not a stand-alone cure)
Neuroinflammation and vascular inflammation are part of how many dementias progress. Helix treats the sources that can actually be changed:
- Tight control of blood pressure, glucose, and lipids
- Weight and visceral-fat reduction when obesity is driving metabolic inflammation (including diet and, when appropriate, GLP-1 therapy as part of a broader metabolic plan)
- Treatment of sleep apnea
- Smoking cessation and reduction of heavy alcohol use
- Dental/periodontal care when chronic oral inflammation is present
- Review of autoimmune, infectious, or medication-related inflammatory contributors
- An eating pattern that supports vascular health (typically Mediterranean style: plants, fish, olive oil, limited ultra-processed food)
This is targeted reduction of inflammatory drivers, not routine high-dose NSAIDs, unproven “anti-inflammatory IVs,” or supplements marketed to “reverse dementia.” Chronic NSAID use is not a recommended dementia treatment and can harm older adults. Anti-inflammatory supplements are used only when there is a documented deficiency or a separate medical indication—not as a substitute for diagnosis and standard therapy.
Lowering inflammatory burden will not reverse established neurodegeneration. It can support vascular brain health, improve energy and sleep for some patients, and make other treatments safer and more effective.
Symptom-focused medications (widely used)
For Alzheimer’s-type dementia, FDA-approved options include cholinesterase inhibitors (donepezil, rivastigmine, galantamine, and related agents such as benzgalantamine) and memantine for moderate to severe disease. These do not stop the disease. They may modestly help memory, attention, or daily function for a period of time in some patients.
Disease-modifying therapy for early Alzheimer’s (selected patients)
Lecanemab (Leqembi) and donanemab (Kisunla) are FDA-approved anti-amyloid antibodies for early Alzheimer’s (mild cognitive impairment or mild dementia due to AD) with confirmed amyloid pathology. They can slow decline by a modest amount. They require careful selection, monitoring for brain swelling or bleeding (ARIA), and structured follow-up. They are not appropriate for advanced dementia and are not a cure.
Helix Advanced Medicine evaluates whether this pathway is relevant and coordinates specialty care, infusion or injection logistics, and safety monitoring when a patient is a candidate.
Behavior, safety, and caregiver support
Agitation, sleep disruption, driving risk, medication management, and caregiver strain are part of treatment. Non-drug strategies come first when possible. When medication is needed for Alzheimer-related agitation, FDA-approved options may be considered in appropriate patients, used with caution in older adults.
Vascular and mixed dementia
Blood pressure, diabetes, lipids, smoking cessation, stroke prevention, and reduction of vascular inflammation remain the core of treatment when vascular injury is driving decline.
Who this program may be for
- Adults who want a prevention / brain-health plan (family history, vascular risk, metabolic inflammation, or midlife optimization)
- People with new memory or thinking changes who need a medical evaluation
- Patients with diagnosed MCI or dementia who need a clear treatment and monitoring plan
- Families who need help with medications, safety, and next-step decisions
What to expect at Helix Advanced Medicine
- 01Consultation — goals, history, current function, and family observations
- 02Workup — exam, cognitive screening, labs, medication review, and assessment of inflammatory/metabolic drivers
- 03Plan — risk-factor and inflammation-reduction targets, treatment options by stage, and referrals when specialty testing or infusion therapy is indicated
- 04Follow-up — interval reassessment, side-effect monitoring, and adjustment as cognition or function changes
Plans are individualized. Two people with “memory problems” often need entirely different care.
